Breadcrumb Home Studies Studies Search Filter Research Area AllBrain and Mental HealthCure and ImmunotherapyTherapeuticsTuberculosis Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentOpen to AccrualParticipants Off Study and Primary Analysis CompletedWithdrawn Sort Study Number AscStudy Number Desc Submit Search Showing 18 studies. IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number TBD Research Area Tuberculosis Study Status In Development IMPAACT 2049: LEAP DAIDS Number TBA Research Area Tuberculosis Study Status In Development IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status Withdrawn IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Withdrawn IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development Pagination Current page 1 Page 2 Next page Next
IMPAACT 2051: Phase II Study of the Pharmacokinetics, Safety, Tolerability, and Anti-Mycobacterial Activity of Pretomanid with Bedaquiline, Linezolid, with or without Moxifloxacin (BPaL/M) in Children with Rifampicin-Resistant Tuberculosis DAIDS Number TBD Research Area Tuberculosis Study Status In Development
IMPAACT 2039A: Phase I Study of the Safety and Immunogenicity of HIVconsvX Vaccines and the Safety and Pharmacokinetics of Broadly Neutralizing Antibodies in Children Living with HIV DAIDS Number 39194 Research Area Cure and Immunotherapy
IMPAACT 2037: Open-Label, Phase I Study of the Safety and Pharmacokinetics of PGT121.414.LS alone and in combination with VRC07-523LS in Infants Exposed to HIV-1 DAIDS Number 38962 Research Area Therapeutics Study Status Enrolling
IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Withdrawn
IMPAACT 2034: Phase 1 Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis DAIDS Number 38754 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2028: Long-Term Clinical, Immunologic, and Virologic Profiles of Children who Received Early Treatment for HIV DAIDS Number 38693 Research Area Cure and Immunotherapy Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum. DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Follow Up
IMPAACT 2020: Phase II Study of Shortened Oral Treatment for Rifampicin-Resistant Tuberculosis in Children DAIDS Number 38505 Research Area Tuberculosis Study Status In Development
